Phase I Dose Escalation of Single Fraction Adjuvant Stereotactic Body Partial Breast Irradiation Early Stage Breast CA
Radiation, Stereotactic Body Radiation Therapy.
Early Stage Breast Cancer
RADIATION: Stereotactic Radiation
maximum tolerated dose, maximum tolerated radiation dose, 3 years
dose-limiting toxicity, dose-limiting toxicity for each dose level, 90 days|cosmesis, as evaluated by an independent panel judging from serial photography, follow up at month 3, 6, 12, 24, 36, 48, and 60
breast recurrence rate, 5 years|distant disease-free interval, the time from registration to first diagnosis of distant disease, 5 years|recurrence free survival, time from registration to first diagnosis of a local, regional, or distant recurrence, 5 years|overall survival, time from registration to death due to any cause, 5 years|treatment related fibrosis, Strain elastography, an imaging modality, which will be utilized to determine different degrees of treatment related fibrosis., follow up at month 6, 12, 18, and 24
In this protocol, we plan to use the uniqueness of the Cyberknife system to deliver an adjuvant single fraction radiation dose. We anticipate that this radiation deliver system will reduce toxicity and improve cosmesis. Extrapolating from an intra-operative body of work, this Phase I study will attempt to achieve a non-invasive low toxicity profile and maintain good to excellent cosmesis. In this effort, the Cyberknife system will be used to achieve high conformality and dose gradient.